Among the top deals this year includes a partnership between Roche AG and Chiasma Inc., of New York, that could generate a total of $595 million

TNI BioTech Inc., of New York, named Joseph M. Fortunak a strategic consultant

N30 also is remarkable for raising funding entirely from "New York-based private capital," including Deerfield Capital Management LLC and its founder, Arnold Snider

Bristol-Myers Squibb Co. (BMS), of New York, disclosed results from a 12-month subgroup analysis of a National Institutes of Health, open-label, long-term research study of metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD

Bristol-Myers Squibb Co., of New York, said the FDA approved a supplemental new drug application for the HIV-1 therapy Sustiva (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg

LLC acted as exclusive placement agent 4/19/13 Ohr Pharmaceutical Inc. (New York) Exercise of Series B warrants N/A $5.05 Ohr raised about $5.05M from institutional and accredited shareholders through the exercise of Series B warrants 4/23/13 OxiGene Inc. (South San Francisco) Private placement of zero coupon convertible preferred stock Convertible into 1.38S $5 OxiGene raised $5M through the placement

Among the top deals this year includes a partnership between Roche AG and Chiasma Inc., of New York, that could generate a total of $595 million

Stifel $60 $502.08 Durata Therapeutics Inc. (Chicago; DRTX)6 4/12/13 4/12/13 7.15S $7 25.55 BofA Merrill Lynch Credit Suisse (co-lead) Jefferies (co-lead) JMP Securities RBC Capital Markets $50.05 $178.85 iBio Inc. (Newark, Del.; IBIO)7 7/26/11 4/23/13 8.925U $0.48 47.77 Roth Capital Partners $4.28 $22.93 MEI Pharma Inc. (San Diego; MEIP) 5/26/11 4/5/13 2.03S $7.50 17.07 Stifel Cowen and Co. (co-lead) Roth Capital Partners $15.2 $128 NeoStem Inc. (New York; NYSE:NBS)8 10/3/12 4/30/13 21.5S

New York $8.5 Anterios raised $8.5M in a financing from Ascent Biomedical Ventures, DRW Trading Group, Praesideo Private Equity Partners, Quantum Technology Partners, Scientific Health Development and the Spring Bay Companies 4/25/13 Aquinox Pharmaceuticals Inc

and Memorial Sloan-Kettering Cancer Center in New York entered a partnership in hematologic cancers

with Forest Laboratories Inc., of New York, that was approved by the FDA in August 2012 in the dual indications of CIC and IBS-C in adults

Adamas Pharmaceuticals Inc., of Emeryville, Calif., and Forest Laboratories Inc., of New York, partnered to develop a fixed-dose combination of Namenda XR (memantine) and donepezil (MDX 8704) for dementia of Alzheimer's in the U.S. In his presentation, Greg Went, CEO of Adamas, said company leaders realized the market for MDX8704 was not really specialized neurology, but primary care

and Canada in partnership with the Leukemia and Lymphoma Society, which has previously supported the development of CPX-351 . (See BioWorld Today, Dec. 27, 2012.) The transaction, led by New York and San Diego-based life sciences venture capital firm Valence Life Sciences LLC, sold a total of 10,430,034 shares of common stock at $3...NeoStem Inc., of New York, reported the partial exercise of the overallotment option granted to the underwriters to purchase an additional 1.5 million shares of its

Almirall SA, of Barcelona, Spain, and Forest Laboratories Inc., of New York, reported positive topline results from AUGMENT COPD, the second six-month pivotal Phase III trial evaluating the efficacy and safety of investigational fixed-dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA), delivered in the Pressair (Genuairn outside the U.S.) inhaler

Tonix Pharmaceuticals Holdings Corp., of New York, said it effected a 1-for-20 reverse stock split, effective May 1, as a step toward its intention to list its common stock on Nasdaq

New York-based Pfizer Inc

New York-based Royalty Pharma, which has made a hostile bid of $7.3 billion for Elan, has explicitly alluded to this in an investor presentation: "If Elan management was raising a fund to go out and buy unknown companies and products around the globe, would you invest $4.4 billion with them

NeoStem Inc., of New York, priced an underwritten public offering of 20 million shares of common stock at 50 cents apiece, seeking to generate $10 million

Pfizer Inc., of New York, presented results from a Phase III study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49